Slide 1: Cencora, Inc. First Quarter Fiscal 2025 Earnings Call
Cencora, Inc. First Quarter Fiscal 2025 Earnings Call February 5, 2025
Slide 2: Cautionary Note Regarding Forward Looking Statements
Cautionary Note Regarding Forward Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Securit
Slide 3: Cencora long-term vision and targeted EPS growth
8% - 12%* targeted long - term adjusted diluted EPS growth Cencora is united in our *Growth rates given on a constant currency basis responsibility to create healthier futures. Long-term vision of Cencora creates unparalleled expanding leadership and access, efficiency, and reliability for growing h
Slide 4: First quarter highlights & strategic overview
First quarter highlights & strategic overview Company highlights Financial highlights & fiscal 2025 guidance • On January 2, 2025, Cencora completed its previously announced • Adjusted diluted EPS(1) increased 13.7% year-over-year to $3.73. acquisition of Retina Consultants of America ("RCA"), a lea
Slide 5: Financial results
cencora Financial results
Slide 6: Q1 fiscal 2025 financial summary
Q1 fiscal 2025 Consolidated results GAAP Adjusted (non-GAAP)(1) financial summary Revenue y/y% $81.5B 12.8% $81.5B 12.8% 12.8% Gross profit $2.6B $2.5B Revenue growth y/y y/y% 3.6% 6.1% 7.2% Operating expenses $1.9B $1.6B Consolidated y/y% 12.5% 5.5% adjusted operating income(1) growth y/y Operating
Slide 7: U.S. Healthcare Solutions segment
U.S. Healthcare Solutions segment Q1 fiscal 2025 financial results Q1 Q1 Financial results y/y% fiscal 2025 fiscal 2024 • Revenue increased 13.6% to $74.0 billion Revenue $74.0B $65.2B 13.6% due to overall market growth primarily driven by unit volume growth, including increased Operating income $76
Slide 8: International Healthcare Solutions segment
International Healthcare Solutions segment Q1 fiscal 2025 financial results Constant Financial results Q1 Q1 y/y% currency(1) (as reported) fiscal 2025 fiscal 2024 • Revenue of $7.5 billion was up 5.5% on an y/y% as reported basis. On a constant currency $7.5B $7.1B 5.5% 8.5% basis, revenue increase
Slide 9: Fiscal 2025 guidance
cencora Fiscal 2025 guidance
Slide 10: Fiscal 2025 guidance
Fiscal 2025 guidance As reported Constant currency(1) Consolidated Revenue 8% to 10% Adjusted operating income(1)(2) 11.5% to 13.5% U.S. Healthcare Solutions Revenue 9% to 11% Operating income 14.5% to 16.5% International Healthcare Solutions Revenue 4% to 5% 7% to 9% Operating income Flat ~5% Bold
Slide 11: Fiscal 2025 guidance continued
Fiscal 2025 guidance continued Fiscal 2025 Guidance Fiscal 2024 Actual Adjusted diluted earnings per share(1) $15.25 to $15.55 $13.76 Net interest expense $290 to $310 million $157 million Adjusted effective tax rate(1) ~21% 20.8% Diluted weighted average shares outstanding Under 196 million 200.3 m
Slide 12: Advancing corporate responsibility initiatives to create healthier futures
Global Corporate Responsibility Building resilient and sustainable operations • Business Resilience: We have performed physical risk assessments using climate models to inform operational planning. • Renewable Energy Initiatives: We continue to explore renewable energy options to enhance sustainabil
Slide 13: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to corporate responsibility Our 5 Strategic Imperatives Why we exist We are united in our responsibility to create healthier futures Advance core
Slide 14: Appendix
cencora Appendix
Slide 15: GAAP to Non-GAAP Reconciliations, Three Months Ended December 31, 2024
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2024 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP 2,55
Slide 16: GAAP to Non-GAAP Reconciliations, Three Months Ended December 31, 2023
CENCORA, INC. GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended December 31, 2023 Income Net Income Diluted Operating Operating Before Income Tax Attributable Earnings Gross Profit Expenses Income Income Taxes Expense to Cencora Per Share GAAP $ 2,
Slide 17: Supplemental information regarding non-GAAP financial measures
Supplemental information regarding non-GAAP financial measures To supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses the non-GAAP financial measures described below. The non-GAAP financial measures should be viewed in
Slide 18: Supplemental information regarding non-GAAP financial measures (cont.)
Supplemental information regarding non-GAAP financial measures (cont.) • Adjusted net income attributable to Cencora: Adjusted net income attributable to the Company is a non-GAAP financial measure that excludes the same items that are described above. Management believes that this non-GAAP financia
Slide 19: Contact
Contact Bennett S. Murphy Senior Vice President Head of Investor Relations & Treasury bennett.murphy@cencora.com